NasdaqGM:NTLABiotechs
A Look At Intellia Therapeutics (NTLA) Valuation After Earnings Beat Trial Progress And FDA Hold Lift
Intellia Therapeutics (NTLA) is in focus after a busy stretch, with Q4 2025 results exceeding earnings and revenue expectations, encouraging hereditary angioedema trial data, and an FDA clinical hold lifted on its partnered gene editing drug.
See our latest analysis for Intellia Therapeutics.
At a share price of $13.42, Intellia has seen a 49.28% 90 day share price return and a 45.71% year to date share price return. However, the 3 year total shareholder return of a 69.49% decline shows that...